Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogs.
作者信息
Fattizzo Bruno, Pasquale Raffaella, Carpenedo Monica, Cantoni Silvia, Auteri Giuseppe, Gramegna Doriana, D'Adda Mariella, Napolitano Mariasanta, Consonni Dario, Ruggeri Marco, Siragusa Sergio, Rossi Giuseppe, Vianelli Nicola, Barcellini Wilma
机构信息
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, UOC Ematologia, Milano.
Ematologia e Trapianto, ASST Ospedale San Gerardo di Monza, Monza.
出版信息
Haematologica. 2019 Oct;104(10):e470-e473. doi: 10.3324/haematol.2019.216804. Epub 2019 Mar 7.
Abstract
摘要
相似文献
1
Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogs.骨髓特征可预测接受血小板生成素类似物治疗的原发性免疫性血小板减少症患者多中心队列的预后。
Haematologica. 2019 Oct;104(10):e470-e473. doi: 10.3324/haematol.2019.216804. Epub 2019 Mar 7.
2
Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura.两名难治性免疫性血小板减少性紫癜患者中，艾曲泊帕和罗米司亭之间不存在交叉耐药性。
Blood Transfus. 2014 Oct;12(4):605-7. doi: 10.2450/2014.0246.13.
3
No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura.在慢性免疫性血小板减少性紫癜中序贯使用罗米司亭和艾曲泊帕后无交叉耐药性。
Blood. 2013 Feb 14;121(7):1240-2. doi: 10.1182/blood-2012-11-465575.
4
Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma.血小板生成素受体激动剂用于控制活动性淋巴瘤患者的免疫性血小板减少症。
Br J Haematol. 2019 Sep;186(6):e217-e219. doi: 10.1111/bjh.16114. Epub 2019 Jul 31.
5
Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.血小板生成素受体激动剂艾曲泊帕、阿伐曲泊帕和罗米司亭在一名慢性免疫性血小板减少症患者中的相对效价。
Br J Haematol. 2018 Oct;183(2):168. doi: 10.1111/bjh.15432. Epub 2018 Jul 5.
6
Thrombopoietin receptor agonist switch in children with persistent and chronic severe immune thrombocytopenia: A retrospective analysis in a large tertiary center.儿童持续性和慢性重度免疫性血小板减少症中血小板生成素受体激动剂的转换：大型三级中心的回顾性分析。
Pediatr Blood Cancer. 2019 Jun;66(6):e27704. doi: 10.1002/pbc.27704. Epub 2019 Mar 11.
7
Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study.妊娠中免疫性血小板减少症使用血小板生成素受体激动剂：一项多中心研究的结果。
Blood. 2020 Dec 24;136(26):3056-3061. doi: 10.1182/blood.2020007594.
8
Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice.新诊断的免疫性血小板减少症患者停用血小板生成素受体激动剂后的无治疗缓解：真实世界临床实践中的观察性回顾性分析。
Int J Hematol. 2020 Aug;112(2):159-168. doi: 10.1007/s12185-020-02893-y. Epub 2020 May 31.
9
"ITP" is not always immune thrombocytopenia.
Am J Hematol. 2020 Dec;95(12):1614-1615. doi: 10.1002/ajh.25872. Epub 2020 Jun 12.
10
Use of eltrombopag after romiplostim in primary immune thrombocytopenia.在原发性免疫性血小板减少症中，在使用罗米司亭后使用艾曲泊帕。
Br J Haematol. 2015 Apr;169(1):111-6. doi: 10.1111/bjh.13266. Epub 2014 Dec 18.
引用本文的文献
1
Clonal hematopoiesis in patients with autoimmune thrombocytopenia: an international multicenter study.自身免疫性血小板减少症患者的克隆性造血：一项国际多中心研究。
Blood Adv. 2025 Feb 11;9(3):488-495. doi: 10.1182/bloodadvances.2024014984.
2
Natural history of chronic idiopathic neutropenia of the adult.成人慢性特发性中性粒细胞减少症的自然病史。
Sci Rep. 2024 Sep 19;14(1):21891. doi: 10.1038/s41598-024-71719-2.
3
Efficacy and safety of cyclosporine A treatment in autoimmune cytopenias: the experience of two Italian reference centers.环孢素A治疗自身免疫性血细胞减少症的疗效与安全性：两家意大利参考中心的经验
Ther Adv Hematol. 2022 May 14;13:20406207221097780. doi: 10.1177/20406207221097780. eCollection 2022.
4
Eltrombopag for the treatment of refractory thrombocytopenia associated with connective tissue disease.依洛尤单抗治疗与结缔组织病相关的难治性血小板减少症。
Sci Rep. 2021 Mar 9;11(1):5459. doi: 10.1038/s41598-021-84493-2.
5
Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation.依鲁替尼在免疫性血小板减少症、再生障碍性贫血和骨髓增生异常综合征中的作用：从巨核细胞生成到免疫调节。
Drugs. 2019 Aug;79(12):1305-1319. doi: 10.1007/s40265-019-01159-0.
本文引用的文献
1
Activity of eltrombopag in severe aplastic anemia.艾曲波帕在重型再生障碍性贫血中的活性。
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):450-456. doi: 10.1182/asheducation-2018.1.450.
2
Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia.血小板生成素水平可预测免疫性血小板减少症患者对艾曲泊帕和罗米司亭治疗的反应。
Am J Hematol. 2018 Dec;93(12):1501-1508. doi: 10.1002/ajh.25275. Epub 2018 Sep 26.
3
Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety.艾曲泊帕在免疫性血小板减少症中的应用：疗效综述及药物安全性更新
Ther Adv Drug Saf. 2018 Jun;9(6):263-285. doi: 10.1177/2042098618769587. Epub 2018 Apr 19.
4
Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.在一项随机双盲试验中，对接受罗米司亭或安慰剂治疗的低风险骨髓增生异常综合征血小板减少患者白血病进展风险进行长达5年的长期随访。
Lancet Haematol. 2018 Mar;5(3):e117-e126. doi: 10.1016/S2352-3026(18)30016-4. Epub 2018 Jan 26.
5
Prognostic impact of bone marrow fibrosis and dyserythropoiesis in autoimmune hemolytic anemia.骨髓纤维化和红细胞生成异常在自身免疫性溶血性贫血中的预后影响
Am J Hematol. 2018 Aug;93(4):E88-E91. doi: 10.1002/ajh.25020. Epub 2018 Jan 10.
6
Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice.艾曲泊帕在临床实践中用于持续性及新诊断免疫性血小板减少症的疗效与安全性。
Int J Hematol. 2017 Oct;106(4):508-516. doi: 10.1007/s12185-017-2275-4. Epub 2017 Jun 30.
7
Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.艾曲泊帕添加至标准免疫抑制方案用于治疗再生障碍性贫血
N Engl J Med. 2017 Apr 20;376(16):1540-1550. doi: 10.1056/NEJMoa1613878.
8
Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists.超越免疫性血小板减少症：血小板生成素受体激动剂不断演变的作用
Ann Hematol. 2017 Sep;96(9):1421-1434. doi: 10.1007/s00277-017-2953-6. Epub 2017 Mar 8.
9
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.艾曲泊帕与安慰剂治疗血小板减少的低危骨髓增生异常综合征（EQoL-MDS）：一项单盲、随机、对照、2期优效性试验的1期结果
Lancet Haematol. 2017 Mar;4(3):e127-e136. doi: 10.1016/S2352-3026(17)30012-1. Epub 2017 Feb 3.
10
Clinical evolution of autoimmune cytopenias to idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and bone marrow failure syndromes.自身免疫性血细胞减少症向意义未明的特发性血细胞减少症/发育异常（ICUS/IDUS）及骨髓衰竭综合征的临床演变。
Am J Hematol. 2017 Mar;92(3):E26-E29. doi: 10.1002/ajh.24618. Epub 2017 Feb 3.
Zotero 插件